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Advanced biomedical applications based on
emerging 3D cell culturing platforms
Anheng Wang, a Leigh A. Madden b and Vesselin N. Paunov *a
It is of great value to develop reliable in vitro models for cell biology and toxicology. However, ethical issues
and the decreasing number of donors restrict the further use of traditional animal models in various fields,
including the emerging fields of tissue engineering and regenerative medicine. The huge gap created by the
restrictions in animal models has pushed the development of the increasingly recognized three-dimensional
(3D) cell culture, which enables cells to closely simulate authentic cellular behaviour such as close cell-to-cell
interactions and can achieve higher functionality. Furthermore, 3D cell culturing is superior to the traditional
2D cell culture, which has obvious limitations and cannot closely mimic the structure and architecture of
tissues. In this study, we review several methods used to form 3D multicellular spheroids. The extracellular
microenvironment of 3D spheroids plays a role in many aspects of biological sciences, including cell
signalling, cell growth, cancer cell generation, and anti-cancer drugs. More recently, they have been explored
as basic construction units for tissue and organ engineering. We review this field with a focus on the previous
research in different areas using spheroid models, emphasizing aqueous two-phase system (ATPS)-based
techniques. Multi-cellular spheroids have great potential in the study of biological systems and can closely
mimic the in vivo environment. New technologies to form and analyse spheroids such as the aqueous two-
phase system and magnetic levitation are rapidly overcoming the technical limitations of spheroids and
expanding their applications in tissue engineering and regenerative medicine.
1. Introduction
1.1 The spheroid model
After the concept of the 3D cell spheroid model was introduced,
various attempts have been made to simplify the generation
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of spheroids. With the increasing yield and decreasing lab cost
of spheroids, they have been increasingly employed in different
fields including clinical trials, biomedical science, pharmacology,
and personal disease care. The ultimate purpose of spheroids is
tissue engineering and regenerative medicine applications.1,2
Compared to the traditional 2D cell culture, the condensed
packed spheroids have the merits of better replicating the
extracellular microenvironment, which are considered to be
highly associated with cell growth and cell signalling.3,4 Since
the knowledge on preparation methods, imaging, different assays
and maintenance of spheroids has greatly improved, major
attempts have been made to investigate the in vivo implantation
of spheroids in various animal models, including rats and rabbits
to study tissue regeneration.5 Cell spheroids, also known as
multicellular spheroids (MCS), are the simplest in vitro model
of solid cell clusters. Spheroids are generated due to the
production of several key proteins including fibronectin and
collagen to form intercellular adhesions and self-assemble into
compact aggregates.
Generally, the progress achieved is based on a non-adherent
surface or within a 3D matrix, which can conveniently produce
spheroids with different sizes ranging from the micrometre to
millimetre scale.6 Since spheroids grow to around 100 mm, their
depth causes their different parts to experience non-uniform
concentrations of soluble factors. The unavailability of oxygen
deep inside spheroids results in a hypoxic core. Thus, to over-
come this issue, there have been various attempts to vascularize
the in vitro 3D spheroid model to maintain spheroids with a larger
size.1 Additionally, spheroids offer the flexibility of incorporating
different stromal components to accommodate studies on how
physical interactions between cancer cells and tumour stroma and
intercellular signalling regulate tumour growth, angiogenesis,
invasion, and drug resistance.7,8
Due to these advantageous features, there has been a major
trend to utilize spheroids as surrogate tumour models in tissue
engineering and regenerative medicine. However, after ten
years of development, the field is still used empirically rather
than theoretically. This is because the concept of spheroids
precedes technology. Since the first bioprinters were used to
produce spheroids, no major progress has been achieved in this
area. All variants (inkjet, micro-extrusion and laser-assisted) are
just modified versions of the prototype 3D printers. Thus, the
stagnation of bioprinting technology has halted the development
of spheroid technology. A scaffold-free and lab-friendly bioprinter
with high throughput is the key the further development of
spheroids. More importantly, scaffold-based techniques make
it inherently difficult to boost the yield of spheroids, which
consequently limit the application of spheroids to simple drug
testing. Recently, spheroids have been shown to be suitable for
use as individual blocks in tissue formation; however, at low
yields, and thus a lack of bricks makes it hard to build a ‘‘wall’’.
1.2 Purpose of this review
A scaffold-free and lab-friendly bioprinter with high throughput
was not available until the invention of the microneedle-based,
non-scaffold-based ‘Kenzan’ bioprinter.9 This technique could
fuse spheroids into cellular aggregates without any scaffold and
synthesize their extracellular matrix directly. This breakthrough
in bioprinting techniques can manipulate spheroids into the
required architecture with great robustness. This novel technology
opens wide opportunities for the bio-engineering of tissues and
organs. Simultaneously, higher requirements especially the yield
result in high standards for the manufacturing of spheroids.
Recently, researchers have developed several scaffold-free
techniques using spheroids for achieving a larger yield with
controlled cell cluster sizes and properties.
Herein, we do not review all the techniques for spheroid
culture. Impressive comprehensive reviews have been discussed
by others.11,86,105 Instead, we focus on multicellular spheroids
formed without a scaffold, especially recently developed aqueous
two-phase system (ATPS)-based techniques, and further discuss
the applications of high-throughput spheroids in order to widen
the applicability of spheroids in biomedical research.
2. Current methods to generate MCS
Simple and high yield methods for generating MCS are a
prerequisite for spheroid applications. Preventing cells from
attaching to the culture ware substratum is the basic require-
ment for the generation of MCS. For a higher standard in the
generation of spheroids, the production efficiency, MCS size
uniformity, possible cellular damage, yield rate, efficiency, cyto-
toxicity, cell growth, efficiency and applicability should all be
considered. There are several excellent review papers on the
fabrication methods for spheroids.10–12 Thus, here we mainly
discuss scaffold-free techniques, emphasizing ATPS- and magnetic
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levitation-based techniques and their applications (see Scheme 1).
Table 1 summarizes the current scaffold-free MCS generation
techniques together with their advantages and shortcomings.
2.1 The hanging drop method
The hanging drop is the most commonly used method to
generate spheroids. This method relies on gravity and upside-
down droplets to force cells into spheroids.13 During the formation
of aggregates, a small number of cells are hung upside down on
the cell culture plate. Due to surface tension, droplets remain
attached to the cell culture plate and the cells are forced to
aggregate into spheroids under the influence of gravity. Without
a robotic system, this method is considered to be quite labour
intensive. Cells gradually grow over several days to form large
aggregates.6,14 The growth of spheroids can be easily monitored in
the droplets. A variety of cell types have been proven to be able to
form spheroids using this method including both Hep-G2 and
HEK.8,15,16 Different cell types can be co-cultured or even tri-
cultured in a droplet to form heterotypic spheroids. The convenience
of observation to easily harvest the cell spheroids whenever they
have grown to sufficient size and structure is an advantage.
Spheroid size and composition are mainly controlled by adjust-
ing the initial cell density and growth time in each droplet.
However, due to methodological limitations, the hanging drop
method has difficulty producing large numbers of spheroids
simultaneously.13 Another limitation of this method is the high
demand for equipment.
2.2 Non-adhesive wells
The generally used Petri dishes and culture plates can only
culture 2D cell plates. Specifically, they are treated, and a non-
adhesive is formed, and then they are suitable for generating
MCS.17–21 This protocol has been widely used for different types of
spheroid culture. Culture ware can be easily made non-adhesive
for cells by coating them with agarose thin films17 and hydro-
phobic polymers, including poly(2-hydroxyethyl methacrylate)
(PHEMA)22 and poly-Np-vinylbenzyl-D-lactonamide.10 After the for-
mation of the film, different types of cells can be gently seeded in
the wells. In this simple culture method, the cultivation time and
the number of initial cells are the main factors affecting the
structure and size of the spheroids.10 This method possesses low
requirements for laboratory conditions and can be performed in
Scheme 1 Preparation techniques and various applications of cell spheroids.
Table 1 Current methods for the preparation of cell spheroids
Method Advantages Disadvantages Ref.
Hanging drop Fast spheroid formation Labour intensive, low yield 6, 8 and 13–16
Co-culture, easy to monitor Special equipment needed
Non-adhesive wells Inexpensive, easy to handle Variation in size/shape, low yield 10 and 17–22
Rotating wall vessel Mass production Special equipment needed 23–26
Long term culture, co-culture Variation in size/shape, high shear force
Micro-fluidics High yield, good size control Special equipment needed 9 and 27–30
Easy to monitor Labour intensive
Magnetic levitation Formation of complex shapes Low yield 31–34
Good size control, co-culture Special equipment needed
Aqueous two-phase system (ATPS) Ultra-high yield High shear force 48–63
Co-culture
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most labs. However, the spheroids generated by this method
usually display broad size distributions due to the inaccuracy of
the coated film. Consequently, the spheroids characteristics may
not be well controlled.
2.3 Rotating wall vessel
The rotating wall vessel creates a microgravity environment,
similar to an upgraded version of the hanging drop method.
The environment can maintain cells in suspension and allow
cells to firstly aggregate into spheroids upon slow rotation
B15 rpm.23 As a globule begins to grow, its size and mass
subsequently increase. After this point, the low speed is not
capable of rotating the spheroids. Thus, the speed has to be
gradually increased in the range of 15 and 25 (rpm).24–26
However, due to the complexity of this method, additional
equipment is needed. Spheroids from a series of cells including
mesenchymal stem cells and HUVEC have been formed using
this method. Vascularized spheroids can be formed by the
co-culture of cancer cells and endothelial cells.23–26 Stem cell culture
is possible, and the conditions can be controlled by changing the
medium, which is essential for controlled differentiation. This
method produces aggregates in a low shear environment, which
is basically harmless to most cells. However, the monitoring of
the spheroids during culture is quite difficult due to the rotation;
meanwhile, the low yield and variable size are due to the
same reason.
2.4 Microfluidic-based methods
Microfluidics involves flowing cells through a series of micro-
channel networks into micro-chambers. The micro-chambers can
be designed into different shapes to partition the cells and cause
them to aggregate.27 It is worth mentioning that some microfluidic
devices use a non-adhesive surface to form spheroids.106–108
This method has been proven to work for primary cells, cancer
cell lines, and the co-culture of multiple cell types.9,16,19,27 The
accuracy of microfluidic devices allow the production of precise
size-controlled spheroids for high throughput analysis. Optional
equipment such as biosensors and imaging systems can meet the
needs of observation and testing.28 Additionally, the circulatory
system can import fresh culture medium to control the soluble
factors surrounding the spheroids.16,23 This method also
shows high efficiency for drug testing and the co-culture of
spheroids.13,27,29,30 The biggest merit of the microfluidic-based
method is that it can accurately control the size of the formed
cell spheroids, while having high yield, which can be easily
altered by the device configuration. However, the capacity of the
microfluidic method for the production of large quantities of
cell spheroids required for tissue engineering is limited.
2.5 Magnetic levitation
Magnetic technology is used in various medical fields due to its
biocompatibility. Magnetic levitation is based on bioinorganic
hydrogels composed of bacteriophages (phages) plus magnetic
iron oxide (MIO; Fe3O4, magnetite) and gold nanoparticles, which
self-assemble into hydrogels and can potentially be adapted for
high-throughput screening/high content screening31 (Fig. 1). Also,
substances such as poly-L-lysine can also be used on particles to
encourage cells to attach to the nanoparticles. Magnetic nano-
particles are treated to incorporate individual cells.32–34 Subse-
quently, the cells are forced to aggregate by changing the
magnetic force via a magnet. The advantage of this technology
is that it can control the size and form of spheroids by applying
different magnetic forces and further induce cells to adhere
together and generate dense tissue.31–33
However, the presence of magnetic particles can be concern
for the application of the resulting cells.
Fig. 1 (a) Schematic showing the spheroid generation platform using magnetic nanoparticles and iron pins.35 Reprinted with permission from ref. 35;
Copyright 2013 Elsevier. (b) Magnetic bright-field and fluorescence images of human glioblastoma cells (green; GFP-expressing cells) and normal human
astrocytes (red; mCherry-labelled) cultured separately and then magnetically guided together. (c) Confrontation between human glioblastoma cells and
normal astrocytes monitored for different times.31 Reprinted with permission from ref. 31; Copyright 2015 Springer Nature.
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2.6 Aqueous two-phase system (ATPS)
Martinus Willem Beijerinck accidentally discovered the ATPS
while mixing an aqueous solution of starch and gelatine in
1896. After decades, it was then applied for the first time by
Per-Åke Albertsson. Since then, ATPS has gradually attracted
attention and widely used in various industries.36–38 At high
concentrations, this systems can be formed easily by shearing a
variety of substances in water.39–41 Most of the research on
ATPS has been focused on the separation of substances and
purification products based on two incompatible polymer solutions
and polymer–salt aqueous systems (e.g., phosphate, sulphate or
citrate) with advantages over conventional extraction techniques.
After a long period of development, some researchers have found
that the biocompatibility of ATPS can allow it to be applied in
the field of biomedical research.42,43 Its applications is based on
its main component, water, since the organic solvent used in
conventional extraction can cause serious damage to the viability
of cells.42
In the biological application of ATPS, the most frequently
mentioned system is formed using polyethene glycol (PEG) and
dextran (DEX). At a certain concentration, the miscibility of the
solution results in the formation of two phases. High concentrations
of polymers and salt solutions are also commonly used in
biaqueous systems, but they are obviously not biocompatible.
In the DEX–PEO system, because of the steric exclusion between
the two molecules, polymers start to separate into two different
phases. The phase diagram is shown in Fig. 2, which mainly
shows the properties of ATPS under certain conditions. ATPS
systems may behave entirely different at different temperature
and pH. The phase diagram shows information such as at what
concentration are the two phases capable of producing ATPS.43,45
ATPS can also be used to generate water–water emulsions, and
phase transitions occur when the concentration difference between
the two phases is too large. A binodal curve (TCB) divides the region
of the concentration of the two phases.
2.6.1 Cell partitioning in ATPS. One of the main advantages
of using ATPS in generating cell spheroids is the spontaneous
partition of cells.44 Thus far, only a few studies have been
conducted about the cell partitioning in the ATPS.46,47 There is
no good comprehensive theory on an ATPS system containing
cells. The work done by Atefi and co-workers demonstrated that
the interfacial tension varies at different polymer concentrations
of the two immiscible phases, which will influence the partition
behaviour of cells, e.g. increasing the interfacial tension will
cause cell accumulation at the interface (Fig. 2b–d).44
Iqbal et al. showed that the partition behaviour is deter-
mined by electrochemical, hydrophobicity, bio-specific affinity,
and molecular weight, and it is conformation dependent.114
Increasing the interfacial tension reduces the resistance of cell
movement and pushes them to the interface. In the formation
of spheroids in ATPS, partition behaviour is a prerequisite. Due
to the influence of gravity and surface properties of different
cell types, the partition behaviour may vary.
2.6.2 ATPS-based techniques to generate cell spheroids
2.6.2.1 Microfluidic devices. By using microfluidic devices,
the size of droplets can be controlled to shrink, burst or
grow.48,49 Based on this control, several microfluidic devices
have been optimized to use aqueous two-phase systems to
Fig. 2 (a) Schematic representation of the phase diagram. Concentrations above the binodal curve (TCB) form aqueous two-phase system clashes.41 (b)
Schematic of cell partition experiments with aqueous two-phase systems. (c) Images of A431.H9 cells recovered from the top phase, interface, and
bottom phase of the 5.0% PEG–6.4% DEX two-phase system and loaded on a hemo-cytometer counting. (d) Percentage of A431.H9 cells partitioned to
each of the two bulk phases and their interface in four two-phase systems vs interfacial tension.44 Reprinted with permission from ref. 44. Copyright 2015
American Chemical Society.
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generate spheroids.50–53 This approach is based on the use of a
polymeric ATPS (DEX/PEG) to confine the cells within a
nanolitre-volume aqueous drop immersed within a second,
immersion aqueous phase in close proximity, and cells aggregate
to spontaneously form a spheroid. The commonly used bio-
available ATPS is polyethene (PE) and dextran (DEX) due to the
strong partition of cells to dextran in this system. An ATPS
consisting of DEX and PEG was reported for the preparation of a
cell-laden microgel using microfluidic devices, which involved a
periodically changing injection force.50,52 The microfluidic devices
will overcome the issue of low interfacial tension between the two
phases. The microfluidic device chamber can pump out fluids with
different injection conditions, which can control the size of
droplets. Recently, Tomasi et al. describe a microfluidic droplet
by combining microfluidic devices and an imaging system. This
data-driven approach allowed the heterotopic 3D cell culturing
behaviour to be monitored and linked single-cell measurements
with population measurements.100
This platform yielded time-resolved, single-cell data, revealing a
dynamic response regulated at the spheroid level. This was
achieved by introducing a new asymmetric design for the anchors,
which led to a qualitative transformation in the functionality of the
microfluidic approach for a range of biological applications,
including tissue engineering, models of immuno-therapies, and
understanding host–pathogen interactions. The combination of
precise control of single spheroids and high-density spheroids
within this chip enabled quantitative observations of the
dynamics of drug imposing to tumour spheroids model.
Another recent attractive work on microfluidic devices was
introduced by Cristaldi et al., which could gather crucial information
about cell spheroids, such as density, size, and weight.101
This technique is based on the detection of the terminal
velocity of a free-falling sample in a specifically conceived
analysis flow-channel. The device was proven to be capable of
measuring cell spheroids with a size ranging from 20 to 200 mm
in diameter. To achieve this, the crosslinking reagents horse-
radish peroxidase (HRP) and H2O2 were firstly added to the DEX
and PEO phase, respectively. Then the suspension was mixed
without disturbing the ATPS system (Fig. 3a and b). Due to the
resistance of the ATPS, cells were encapsulated in the microgel
and maintained high viability and proliferation rates. Low
concentrations of gelatine derivatives could be incorporated
Fig. 3 (a) Production of microgel using DEX/PEG-based ATPS in microfluidic devices.50 Reprinted with permission from ref. 50. Copyright 2017 Springer
Nature. (b) Morphology of pre-gelated droplets passing through the narrowest channels in the downstream of the microfluidic device. (c) Schematic of
the all-aqueous-phase microfluidic system for the fabrication of core–shell capsules. (d) Actual fabrication process of core–shell capsules with the help
of a solenoid valve.54 Reprinted with permission from ref. 54. Copyright 2019 American Chemical Society. (e) Acoustic-fluidic device workflow for
forming spherical hydrogels with encapsulated cells.52 Reprinted with permission from ref. 52. Copyright 2019 American Chemical Society.


































































































This journal is©The Royal Society of Chemistry 2020 J. Mater. Chem. B
into the microgel, which promoted the cell adhesion properties
of the microgel. Another microfluidic device based on all
aqueous phases was designed by creating a shell-core structure.
By encapsulating cells in the core phase, the shell phase was
gelated to maintain the structure and induce the formation of
spheroids (Fig. 3c and d).
Recently, De Lora et al. designed an original microfluidic
device connected to smart devices. The electrical signals were
driven by an amplified output of a waveform generator or even
a smartphone, which provided acoustic modulation to generate
an ATPS into multicellular tumour spheroid (MTS) template
droplets (Fig. 3e).52 This method is the first microfluidic device
that could be artificially controlled by a smart phone. It uses
handy acoustic components, which are basically achievable in
most labs.
2.6.2.2 Microdroplet method. The microdroplet method
mainly utilizes gravity and cell partition behaviour in the ATPS,
driving cells to accumulate at the apex and increase the cell/cell
contact.55–57 The alteration of the buoyancy force effect by
altering the concentration of the two phases helps cells accumulate
at the apex. Most of the cells would be trapped at the interface at
the DEX drop meniscus after 4 h of culture in the system. At this
stage, the gravity and surface tension from the interface are
competing with the cells, which confine the cells at the interface
due to the resultant force. DEX is a polysaccharide, which can
attract more cells than the PEG phase, and thus a contact angle
forms between the two phases.44,47 Different cells and different
concentrations of the two phases change the contact angle, similar
to the oil/water emulsion system. The formation of this contact
angle exerts surface forces in a tangential direction to the contact
point. Therefore, the main forces can be simplified as a free body
diagram. As a result of this force interaction, a cell trapped at the
interface moves along the phase interface until it reaches the apex
of the DEX drop meniscus, where the forces are balanced
(Fig. 4e). One to two days after pattern formation, most of the
cells will gather at the apex of the DEX drop and form a tight
cell spheroid or loose cell aggregate, depending on the cell
characteristics. By changing the DEX/PEO phase concentration,
the density of the two phases can easily be adjusted, thus
making this method technically suitable for different types of
cells. However, several cells such as HepG2, which prefer to
form aggregates than spheroids, were shown to not be suitable
for this method, highlighting the need to carefully identify
and select cells for the formation of spheroids. However,
this method can allow the growth of spheroids to be easily
monitored. More importantly, the cell density and size of the
spheroids can be easily controlled (Fig. 4a–d). With over 9 days
culture, the spheroids grew to a diameter of 400 mm. Moreover, the
functionality of these spheroids such as RNA expression dramatically
improved compared to the monolayer culture (Fig. 5).
Another ATPS droplet-based method is carried out by pipet-
ting DEX droplets containing cells directly into the PEG phase.
The cells are automatically confined in the DEX droplets and
form spheroids within 24 h (Fig. 5a–d). This method allows easy
control of the spheroid density, and thus the size of the
spheroids can be manipulated. Also, monitoring and various
testing in this platform are convenient due to the ATPS system.
Fig. 4 (a) Adding PEG/DEX-free fresh medium decreases the density of the DEX-in-PEG ATPS pattern; therefore the floating spheroids settle.
(b) Embryoid body (EB) formation and cardiac differentiation using DEX-in-PEG ATPS pattern. (c) qPCR analysis of representative three germ layer
lineage markers. (d) Representative images of day 12 EBs. (e) Schematic model of ATPS spheroid formation.55
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2.6.2.3 Water-in-water Pickering emulsions. Further research
based on ATPS is the water-in-water (w/w) Pickering emulsion
(Fig. 6). The w/w emulsion is another ATPS system, which
generally consists of two immiscible aqueous phases and one
stabilizer, e.g., protein particles.59–61 The emulsion is generated
by gentle pump using needles to decrease the damage to cells.
This technique initially confines the cells within emulsion
droplets and then increases the concentration of the constant
phase to impose osmotic pressure to fabricate spheroids within
a very short time.62,63 This results in the encapsulation of the
cells in the DEX emulsion drops due to the higher affinity of the
cells to the DEX phase, as mentioned above. Cell–cell inter-
actions are strongly promoted with the emulsion droplets, which
assists the formation of 3D cell clusters, termed clusteroids. The
collected clusteroids were put into an alginate gel to mimic real
tissue generation. The results showed that the area and albumin
linked to cell proliferation were reinforced compared to 2D
monolayer culture. This methodology can potentially extend the
w/w emulsion platform to tissue generation and drug tests. This
technique allows a high yield of cell clusters without harming the
viability of cells. However, only limited types of cells were proved
to work in this technique and the detailed characteristics of the
Fig. 5 q-PCR analysis of expression of (a) CD24, (b) CD133, and (c) Nanog in ATPS spheroids of MDA-MB-157 cells normalized against mRNA levels of a
monolayer of cells. Largest cryosections of 1.5  104 and 1.0  105 cell density spheroids immune-stained for cancer stem cell markers. (d) CD24 (green)
and (e) CD133 (red).56 Reproduced from ref. 58 with permission. Copyright 2016 John Wiley and Sons. (f) Side view of a DEX phase drop in the immersion
PEG phase formed on a glass surface using equilibrated phases from an ATPS with initial composition of 6.4% (w/w) DEX and 5% (w/w) PEG. (g) Top-view
of A431.H9 skin cancer cell spheroid formed with a cell density of 1  104 cells at 24 h. (h) Scanning electron microscopy (SEM) image of A431.H9 cells
after one week of incubation. (i) Spheroids generated using a wide range of cell densities.57 Reproduced from ref. 56 with permission. Copyright 2014
John Wiley and Sons.
Fig. 6 Schematic model of spheroid formation in water-in-water Pickering emulsion. (a) Schematic of high-throughput method for the preparation of
keratinocyte cell spheroids. (b) SEM images of a sample of HaCaT cell clusteroids after being removed from the medium.63 Optical microscopy images of
(c–e) HaCaT cell droplets (5.5 wt% PEO/5.5 wt% Dextran) and (f–h) HaCaT cell clusteroids (10 wt% PEO/5.5 wt% Dextran) stabilized by 2 wt% WP particles.
Here the cell and DEX volume fraction were, fHaCaT = 0.15 and fDEX = 0.25, respectively.
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formed spheroids such as RNA expression, protein, enzyme need
to be further explored.
2.6.2.4 New trends of using ATPS in spheroid application.
Teixeira et al.109 and Pereira et al.110 compared and discussed
novel ATPS-based pattern bioprinting techniques, emphasizing
their potential for three major aspects of (i) cell analysis, (ii) cell
assembly and cell co-culture, and (iii) bacterial co-culture
system.
Among these applications, the most attractive two are spheroid
cultivation and 3D bioprinting. Tavana developed a polymeric
ATPS system that can be used for the high-throughput
fabrication111 of tumour spheroids at the microscale. Similar
to the ATPS microdroplet assay, the cells are confined within
droplets in the DEX phase, which is the bottom phase due to its
higher density. This approach allows more cell–cell interactions,
which will help spheroid formation. However, the major
problem of the ATPS printing system is that it requires special
equipment. Furthermore, the laborious processes of this
equipment is time consuming. Accordingly, another ATPS-based
system implementing a robotic system of a 384-microwell plate
overcame this issue.111,112 Another example of a microtissue
strategy using ATPS includes the use of ATPS to print cell-
containing contractile collagen microdroplets.113
The incorporation of robotic devices in ATPS-based techniques
for 3D cell cultivation is another hot topic. Robotic devices can
further improve the stability and productivity in drug screening
using in vitro cell models.53 Another promising application of APTS
to generate spheroid was reported by Celik et al., where generally,
they embedded significant amounts of spheroids in alginate gel,
which allowed the formation of skin-like tissue.63 These examples
set the scene for the following research on the utilization of ATPS
in the biomaterial field.
3. Co-culture spheroids
After spheroids grow to over 200 mm, a necrotic core may form
because the outer layer of cells hinders nutrient and oxygen
penetration into their core. Moreover, single-cell spheroid systems
are rather limited in simulating the in vivo environment.
Consequently, co-culture or tri-culture assays have been developed
to promote the reliability of spheroid models. Co-culture has
been widely accepted as a successful strategy to boost the
production of genes and proteins in spheroids in vitro in tissue
engineering.15,27,51,64–66 The results of the co-culture are mainly
determined by the types of cells and the patterns of the
co-culture. For example, different cells including endothelial
cells (ECs), human adult keratinocytes (HaCaT), and mesenchymal
stem cells have been co-cultured with hepatocytes,5,66–71 which
either increased the liver-specific functionality such as albumin
production or constructed angiogenesis tissue. In hepatic co-
culture/tri-culture spheroids, the hepatocytes are: (i) pre-mixed
with another type of cells to allow cell self-sorting in the obtained
spheroids. (ii) Culture two/three types of cell spheroids separately
and arrange them in a plate-like or Janus-like structure with an
EC layer or spheres. The ECs will potentiate the growth of the
spheroids under limited oxygen delivery due to vascularization.72
Therefore, ECs are widely thought to be ideal cells for co-culture
with the majority of cell types to prevent the formation of a
necrotic core. The co-culture models enable direct cellular com-
munication via gap junctions and paracrine mechanisms like liver
tissue.102,103 Actual the cell microenvironment not only involves
the metabolism of a single cell and its metastatic potential, it is
usually composed of several types of cells and a scaffold structure
to help the growth of cells. The co-culture or even tri-culture
system can boost the complexity and reliability of spheroid models
to achieve higher accuracy in drug testing and transplantation.
4. Utilization of spheroids
4.1 Drug testing platform for regenerative medicine
Tumour globules have been used as models to simulate tumour
complexity in vitro.69,73
Mixed spheroids of mesenchymal stem cells and cancer cells
have been used to study tumour-mesenchymal cell interactions.
The stem cells provide co-cultured spheroids with enhanced
functionality in protein, RNA and production in vitro.74 Hepatic
cancer cells co-cultured with fibroblasts exhibit an invasive
phenotype, forming tissues similar to primary hepatic cancer
tissues in terms of protein expression in cancer cells.67,69 A
three-dimensional tumour-endothelial model was used to measure
the angiogenic and metastatic potential of tumour cells. The
vascularized structure of the spheroids did not increase the
drug penetration, but the tumour cells were more resistant to
chemotherapy and radiotherapy.75,76
This thick structure compared to the cell sheet strongly
blocked the drug penetration, including the antibodies and
enzymes.36,77 This indicates the tumour-like structure of spheroids
with different cell phenotypes, different proliferation rates
and even different gene expression in different parts of the
rather huge spheroids. Thus, the drug penetrability of
spheroids will be an attractive research topic in the following
decade. Tumour spheroids have been used to measure the
three-dimensional penetrability of anthracyclines using
fluorescence or autoradiography of radio-labelled drugs such as
doxorubicin.104
Personalized medicine has also become an attractive topic
since this approach will help increase the lifespan of patients.
Accordingly, some patient-derived spheroids have been established
and well-characterized. Individual cellular information on spheroids
will be stored in a ‘‘biobank’’. This information can comprise the
entire phenotype of tumor spheroids, and more importantly, the
efficiency of various drugs on the patient-derived spheroid model
will be recorded for future therapeutic options.115–117
4.2 Tissue engineering blocks
Tissue engineering involves the use of large numbers of cells to
simulate organs or tissues in vitro, ultimately transplanting
them into the body of a patient. However, the ideal is plump,
but the reality is bony. The major drawback of tissue engineer-
ing is the low availability of a high density of living cells, for
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example the mono-spheroid diameter is limited to 200–400 mm
due to the restriction of oxygen and nutrients. Thus, to over-
come the limitation of the size of spheroids, endothelial cells
are widely used to vascularize cell spheroids to develop a
capillary-like network.8,66,78–80
The applicable endothelialized spheroids used in clinical
trials are all relatively thin tissues (o2 mm), where the trans-
port of oxygen and nutrients occurs by simple diffusion. These
‘endothelialized’ spheroids can be further fused to form a
larger tissue, which can integrate with the host vascular system
after implantation.68,81–83 Before being implanted, the pre-
vascularization step is crucial.20,84–86 The emerging field of
bioprinting and bio-fabrication is seeking larger clusters of
cells to replace traditional cells to try and fabricate organs
in vitro. Bio-printers, such as inkjet printing and other robotic-
based devices, have been used to print tissue using extracellular
matrix (ECM) with various structures including cell rings and
cell sheets.9,78 Magnetic levitation is an attractive method for
spheroid culture since the magnetic field can easily manipulate
the shape of spheroids (Fig. 7a–e). Magnetic spheroids can be
easily modulated into different shapes.31,32,85,87 Another emerging
technique, ATPS-based generation of spheroids, has also been
demonstrated to be an excellent source for direct-bioprinting. The
bioavailability of ATPS makes it quite achievable to utilize this
system as a type of bio-ink for the fast-formation of tissue
constructs (Fig. 7f).35,58,88,89
Another promising application of spheroids in tissue engineer-
ing is adapting stem cell spheroids for bone generation. In the
human body, compact bone is composed of repeating microscale
units called osteons instead of monolayer cells. These cells are
hierarchically organized into a large bone structure similar to that of
spheroids.118–120 Accordingly, 3D spheroid cell cultures can mimic
key aspects of native bone cellular microenvironments and
hierarchical organization, and thus have attracted a great deal
of attention from researchers in bone tissue engineering.
Hoefner et al. developed human adipose-derived mesenchymal
stromal/stem cell spheroids possessing high adipogenic capacity.
The adipose-derived mesenchymal stromal/stem cells exhibited
enhanced adipogenic capacity and generates adipose-like micro-
tissues, which may be a promising cell delivery strategy for adipose
tissue engineering approaches.121,122 Stem cells can also differentiate
in to many cell types. After stem cells were made into spheroids,
growth factors were added to allow the desired aspect of
differentiation. This unique property makes them functional
building blocks for tissue engineering with great potential.
4.3 In vivo applications
Owing to their many excellent features, spheroids are increasingly
being employed in a wide range of pathological, metabolic studies
in the biomedical area with the ultimate purpose of implantation
(Fig. 8). Cell size is counted when transplanting tissue. Compared
to 2D cells, spheroids can be individually implanted into mamma-
lian animals. Also, since the knowledge about the preparation and
maintenance of spheroids has improved, there has been a plethora
of translational experiments investigating the in vivo implantation
of spheroids into various animal models and tissue generation.
Spheroid transplants have been utilized in almost all human
systems including the cardiovascular system,90 digestive system,91
musculoskeletal system,92 and skin.63,93 However, spheroid
implantation remains a relatively undiscovered field with
limited in vivo published result. Thus, there is unexplored
potential for the in vivo applications of spheroids.
Fig. 7 Magnetic patterning of HeLa multicellular spheroids. (a) Random
distribution of magnetic HeLa spheroids without any applied magnetic
field. 3 day-old spheroids were used. Scale bar represents 500 mm.
(b) Magnetic HeLa spheroids were patterned with an applied magnetic
field within a few seconds. (c) Patterned magnetic HeLa spheroids start to
fuse after 3 h. (d) Fusion and growth of the patterned magnetic HeLa
spheroids after 18 h. (e) Live/dead stain of the fused tissue formed by the
patterned magnetic HeLa spheroids after 48 h of culture. Viable cells are
green, while non-viable cells are red. Scale bar represents 250 mm.32
Reprinted with permission from ref. 32. Copyright 2010 Elsevier. (f) Schematics
of cell printing on a cell monolayer in user-defined shapes. Cell suspension in
the DEX phase is printed onto an existing cell layer by continuous dispensing
from the pipette tip. (g) Fluorescence images of patterned DEX phase on
HEK293H cells spelling ‘‘UMICH’’.58 Reprinted with permission from ref. 58.
Copyright 2019 Springer Nature.
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4.4 Delivery vehicles
Among the studies attempting to extend the limited use of cell
spheroids, applying spheroids as a delivery vehicle is a novel
use. Mesenchymal stem cells (MSC) are widely known their
tumour-homing capability. In the use of MCS therapy, only a
small number of cells and drugs are used in targeting tumours.
A hybrid spheroid/nanomedicine system comprising MSC
spheroids entrapping a drug-loaded nanocomposite to address
these limitations was reported (Fig. 9).95 Generating MSC cells
in spheroids firstly increase their tumour targeting ability and
boost the payload of anticancer drugs.
This system acts as an active drug delivery platform, seeking
and specifically targeting glioblastoma cells, which enables the
effective delivery of chemotherapeutic drugs.
MSC hybrid nanoparticles were fabricated using microflui-
dic devices. This novel approach of using spheroids provides a
new technique. Spheroid-loaded drugs as a ‘‘cruise missile’’ will
be a possible application in the future. Beside this also indicates
a possible way for testing the penetration of therapeutics from
the core of spheroids.
4.5 Biosensors
The increasing attraction that 3D cell culture systems have been
getting results in more problems in how to use in vivo-like spheroids
as a model for biomedical toxicological test with simplicity. The
unique architecture of spheroids is also a hinderance for drug
penetration and antibody action. The challenge with the develop-
ment of in vitro sensors for toxicological tests is the transformation
of different signals into corresponding valid values. Recently, a
biosensor was developed based on the electrochemical monitoring
of the enzymatic activity of non-specific esterases of viable cells. The
enzymatic activity could be easily converted to the viability of
the spheroids.96 Based on this enzyme-based biosensor, it is
convenient to measure the viability of both 2D and 3D cell
culture formats and provide more dynamic data for drug/toxicity
screening. Another type of biosensor works through collecting
measurable analytical signals. The collected signals correspond
to molecular recognition events occurring at the cellular and
molecular levels inside the spheroids.97,98
Michelini and co-workers developed an attractive biosensor
consisting of immobilized spheroids of human cell lines.
Under the regulation of the NFkB pathway and a constitutive
promoter, the spheroid could produce red- and green light-
emitting luciferase, respectively. This dual-signal channel could
enable the researchers to assess the actual toxicity and inflammatory
effects of a sample, rather than identifying single constituents
simultaneously.99
In addition to the usual enzymes and chemical signals, the
mechanical properties of spheroids are also worth studying in
Fig. 8 In vitro therapeutic applications of cell spheroids: spheroid for-
mation methods and organ systems for potential clinical applications.94
Reprinted with permission from ref. 94. Copyright 2018 Elsevier.
Fig. 9 Design and properties of MSC/DNA-templated nanocomposite hybrid spheroid for GBM therapy. (a) Schematic illustration of the hybrid spheroid
system. (b) Representative confocal images of the hybrid spheroids. (C) In vitro tumour targeting of the hybrid spheroids. Scale bar = 50 mm.96 Reprinted
with permission from ref. 96. Copyright 2019 American Chemical Society.
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future works. There has been relevant works focusing on the
stiffness of spheroids with robustness.
5. Future development of
spheroid-based techniques
The increasing biomedical application of spheroids also
presents challenges. To date, 2D cell cultures are still the dominant
cell culture model for drug testing and tissue engineering in
biomedical studies. Also, several challenges restrict the industrial
application of spheroids. Firstly, the fabrication of spheroids must
be cost-effective, lab-friendly and high-throughput. The difficulty
in achieving uniform-size spheroids is another bottleneck because
size is a key feature that affects the diffusion of oxygen and
nutrients inside spheroids and the internal organization of pro-
liferative and necrotic cells.123 Finally, although there have been
years of pre-clinical research, a standard inspection, analytical and
imaging protocol has not been developed. Advanced imaging and
analysis tools for spheroids studies are urgently necessary.
6. Conclusions
With the development of MCS culture techniques, in vitro
models can simulate in vivo characteristics to different degrees.
The formation mechanism of MCS allows researchers to gain
better sight into the cell–cell and cell-matrix interactions. In
addition, MCS simulation of the microenvironment in vitro
enables basic research into cancer biology and tissue develop-
ment, and provides opportunities for pharmacological research
and the in vitro culture of 3D functional tissues. However, this
attractive concept has many challenges. Firstly, the formation
of spheroids requires a higher initial cell density since the cells
number in the MCS structure limits the further expansion of
spheroids. Secondly, the repeatability and quality assurance of
traditional methods are low. Thirdly, the microenvironment
and macro-environment of MCS in existing methods are still
different from that in the in vivo environment, leading to
different cellular behaviours. Current methods cannot achieve
cell migration between MCS. In some mono-spheroid culture
systems, there is a lack of heterogeneous cell–cell interactions,
cell–ECM tissues and cellular signalling pathways. Therefore,
the correlation between in vivo cells and MCS should be fully
demonstrated through the analysis of RNA/DNA expression
profile, protein content, and enzyme content. In addition, low
yield also greatly hinders the study of MCS. Methods for the
fabrication of MCS in vitro have been significantly developed in
the past decade. The integration of the ATPS is considered to be
a promising new approach since it not only can produce
controlled uniform-size MCS, but also restore the complex
cell-matrix/cell–cell interactions, which are vital for the mor-
phology and functionality of MCSs. The physical stress existing
in the ATPS can mimic the in vivo microenvironment and
facilitate MCSs in developing their extracellular matrices,
which are crucial for cell functions. The chambers or droplets
from the ATPS allow the fabrication of MCS in a confined space
to develop controllable uniform-sized MCS. Ultimately, the
higher yields of ATPS can allow researchers to use the micro-
sphere model in a wider range of applications, such as tissue
engineering and toxicological tests. This method can alter the
microenvironment easily, adjusting the osmotic pressure for
MCS formation and growth to mimic the in vivo conditions.
Moreover, the breakthrough in the size and yield control by
advancements in the reviewed techniques such as ATPS and
magnetic levitation create new room for the in vitro application
of MCS, which will be crucial for regenerative medicine and
other clinical applications, ensuring that this exciting area of
research remains relevant for patient care. More elegant designs
for spheroid culture systems such as co-culture/tri-culture MCS
formation are needed to create physiologically relevant micro-
and macro-environments to address the above challenges in the
formation of MCS.
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